Dose Escalation Phase 1 Study of IOA-289 in combination with gemcitabine/nab-paclitaxel

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515674-27-00

Acronym

IOA-289-102

Enrollment

Registered

2024-09-17

Start date

2024-10-01

Completion date

2025-07-22

Last updated

2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic pancreatic cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026